Volition Enhances Board with Dr. Ethel Rubin's Expertise
VolitionRx Welcomes New Independent Director
VolitionRx Limited (NYSE AMERICAN: VNRX), an emerging leader in the field of epigenetics, has announced the appointment of Dr. Ethel Rubin as an independent director on its board. This decision comes as part of the company's strategic initiative to enhance its leadership and governance capabilities.
Dr. Ethel Rubin's Extensive Background
Dr. Rubin brings over 20 years of comprehensive experience in the life sciences sector, showcasing her ability to lead innovations in healthcare. Her background spans various roles designed to enhance operational efficiency and product development across many organizations, from startups to well-established global corporations.
A Milestone in her Career
Throughout her career, Dr. Rubin has significantly contributed to the development and commercialization of health-related technologies. Before joining Volition, she served as Chief Scientific Officer at BioFortis, Inc. (now Q² Solutions). Her expertise was further solidified in leadership roles at notable companies such as CSA Medical, Inc. and Medtronic, plc.
Significant Contributions
During her time at Medtronic, Dr. Rubin excelled in multiple leadership capacities, contributing to global clinical strategy and external innovations. Most recently, she held the position of Head of Ventures at BioHealth Innovation, Inc., leading initiatives to support innovative health solutions through strategic investment opportunities.
Company Praise and Expectations
Volition's Interim Chair, Guy Innes, expressed enthusiasm about Dr. Rubin's joining the board. He stated, "Dr. Rubin possesses profound knowledge of the life sciences industry, and her track record will benefit Volition significantly as we work towards scaling our operations and commercializing our innovative epigenetic solutions. We believe her skill set aligns perfectly with our vision for growth and improvement."
Dr. Rubin’s Vision for the Future
Upon her appointment, Dr. Rubin commented on her excitement about joining Volition. She highlighted the potential of the company's Nu.Q® technology, which is designed to enhance early detection and monitoring of diseases such as cancer and sepsis in both human and animal health. This technology is already generating revenue in the animal health market, and Dr. Rubin sees promising applications for human health as well.
Company’s Innovative Approach
Volition is committed to developing easy-to-use, cost-effective blood tests aimed at diagnosing and monitoring various life-altering diseases. They focus on using innovative technology to allow for early detection, which could significantly enhance patient outcomes.
About Volition
Volition is a multinational company dedicated to advancing the science of epigenetics. Its mission focuses on saving lives and improving quality of life for individuals and animals affected by significant diseases. The company is on a quest to provide early diagnostics and monitor treatment effectiveness to ensure better future health outcomes.
With research and development activities primarily based in Belgium, and other offices located in the U.S., London, and Singapore, Volition is positioned to make a global impact. It aims to be at the forefront of innovative healthcare solutions through continuous research and technology advancement.
Media Contacts
For further information, media inquiries can be directed to Louise Batchelor and Debra Daglish at Volition. They are available for insights into the company's initiatives and Dr. Rubin’s new role.
Frequently Asked Questions
Who is Dr. Ethel Rubin?
Dr. Ethel Rubin is the newly appointed independent director of VolitionRx Limited, bringing over 20 years of experience in the life sciences field.
What role will Dr. Rubin serve at Volition?
Dr. Rubin will be a member of the board of directors, serving on both the Audit Committee and the Compensation Committee.
What is Nu.Q® technology?
Nu.Q® technology is a pioneering nucleosome quantification platform developed by Volition, aimed at early disease detection and monitoring.
Why is early detection important in healthcare?
Early detection of diseases can enhance treatment effectiveness, improve survival rates, and increase the quality of life for patients.
How does Volition plan to grow its operations?
Volition aims to scale its operations through innovative product development and strategic leadership, as evidenced by the recent appointment of Dr. Kelly.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.